Core Viewpoint - The company has established a value management system aimed at enhancing investment value and shareholder returns while ensuring compliance with relevant laws and regulations [2][3]. Group 1: Purpose and Principles of Value Management - The main purpose of value management is to improve company quality, enhance core competitiveness, and solidify the foundation for value management while fostering a strong awareness of shareholder returns [2][3]. - The basic principles of value management include compliance, systematic approach, scientific management, continuity, and integrity [3]. Group 2: Responsibilities and Structure - The board of directors leads the value management efforts, with the management team responsible for execution and the board secretary overseeing the process [5]. - The board is tasked with formulating overall value management plans, monitoring market reflections of company value, and ensuring effective implementation of value management strategies [4][5]. Group 3: Main Methods of Value Management - Key methods for enhancing investment value include mergers and acquisitions, employee stock ownership plans, cash dividends, investor relations management, information disclosure, and share buybacks [6][7][8][9]. - The company aims to focus on its core business, improve operational efficiency, and utilize various strategies to reflect its quality in the market [6][7]. Group 4: Monitoring and Response Mechanisms - The board office is responsible for monitoring key indicators such as market capitalization and price-to-earnings ratios, setting warning thresholds, and initiating response measures when necessary [14]. - In the event of significant stock price declines, the company will analyze causes, enhance communication with investors, and may consider share buybacks or cash dividends to stabilize prices [15][16]. Group 5: Prohibited Actions in Value Management - The company and its stakeholders are prohibited from engaging in misleading information disclosure, insider trading, and other actions that could disrupt market order [18].

Meeting Notification and Attendance - The notification for the 11th meeting of the 9th Board of Directors was sent on August 15, 2025, via phone, email, and verbally [1] - The meeting was held in compliance with the Company Law and Articles of Association, presided over by Chairman Mr. Hao Xiaodong, with the attendance of 5 supervisors [1] Resolutions Passed - The board reviewed and approved the annual report and the summary of the 2025 semi-annual report, which had previously been approved by the audit committee [1] Independent Director Appointment - Independent Director Mr. Zhu Baoxiang has served for six years and applied to resign from his position. The board nominated Mr. Miao Runsheng as the candidate for independent director, pending shareholder approval [2] Share Transfer and Related Transactions - The company plans to transfer its 5% stake in Steel Research Dahui Private Fund Management Co., Ltd. to Steel Research Investment Co., Ltd. for a transaction price based on the net asset valuation of 327.9735 million yuan as of May 31, 2025 [3] - The company will also waive its right of first refusal regarding the transfer of stakes in the private fund by other related companies, which constitutes a related party transaction [3] Upcoming Shareholder Meeting - The company will hold its first temporary shareholder meeting on September 10, 2025, to discuss the election of Mr. Miao Runsheng as an independent director and the transfer of the stake in Steel Research Dahui Private Fund Management Co., Ltd. [4]

Core Viewpoint - Ningxia Orient Tantalum Industry Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, driven by market expansion and product structure adjustments, despite facing challenges in cash flow and rising costs [1][2]. Company Overview and Financial Indicators - The company is primarily engaged in the research, production, and sales of rare metals such as tantalum and niobium, with a strong market position and competitive advantages [3]. - The total revenue for the reporting period was approximately 796.81 million yuan, representing a 34.45% increase compared to the same period last year [2]. - The net profit attributable to shareholders was approximately 137.60 million yuan, a 34.93% increase year-on-year [2]. - Basic earnings per share increased by 30.00% to 0.2886 yuan [2]. Business Operations - The company focuses on the production of tantalum and niobium products, which are widely used in various industries including electronics, aerospace, and energy [3]. - The company maintains strong relationships with international manufacturers, enhancing its market presence [3]. Financial Performance Analysis - Operating income increased due to market expansion and product structure adjustments, with operating costs rising by 36.02% to approximately 649.63 million yuan [4]. - Sales expenses surged by 158.11%, attributed to increased packaging and service costs [4]. - The net cash flow from operating activities improved significantly, showing a 70.21% reduction in cash outflow compared to the previous year [4]. Competitive Advantages - The company has established a strong brand presence and technical expertise in the tantalum and niobium industry, supported by a robust research and development framework [3]. - It has received numerous awards and recognitions, solidifying its reputation in the market [3]. Market and Sales Analysis - Domestic sales accounted for approximately 64.71% of total revenue, while international sales contributed 35.29%, reflecting a balanced market approach [4]. - The company’s product mix includes a significant increase in titanium and titanium alloy products, which saw a 154.69% rise in revenue [4].

Meeting Overview - The third meeting of the board of directors of Xianheng International Technology Co., Ltd. was held with all 8 directors present, complying with legal and regulatory requirements [1][2]. Resolutions Passed - The board approved the "2025 Semi-Annual Report and Summary" with a unanimous vote of 8 in favor [1]. - The board approved the "Special Report on the Storage and Actual Use of Raised Funds for the First Half of 2025," also with a unanimous vote of 8 in favor [2]. - The board approved the establishment of the "Xianheng International Technology Co., Ltd. Market Value Management System" with a unanimous vote of 8 in favor [2]. - The board approved the temporary use of part of the idle raised funds to supplement working capital, with a unanimous vote of 8 in favor [2]. - The board approved the change of accounting firm to Zhihong Accounting Firm (Special General Partnership) for the 2025 financial statement and internal control audit, pending shareholder meeting approval, with a unanimous vote of 8 in favor [3]. - The board approved the proposal to convene the fourth extraordinary general meeting of shareholders in 2025, with a unanimous vote of 8 in favor [3].

亿晶光电科技股份有限公司 市值管理制度 第一章 总则 第一条 为加强亿晶光电科技股份有限公司（以下简称"公司"）市值管理， 切实提升公司投资价值，增强投资者回报，维护投资者利益，根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《上市公 司监管指引第 10 号——市值管理》等法律法规、规范性文件和《亿晶光电科技 股份有限公司章程》（以下简称"《公司章程》"）等规定，制定本制度。 第二条 本制度所称市值管理，是指公司以提高公司质量为基础，为提升投 资者回报能力和水平而实施的战略管理行为。 第三条 市值管理的基本原则包括： （一）合规性原则：公司应当在严格遵守相关法律法规、规范性文件、自律 监管规则以及《公司章程》等内部规章制度的前提下开展市值管理工作。 （二）系统性原则：公司应当按照系统思维、整体推进的原则，协同公司各 业务体系以系统化方式持续开展市值管理工作。 （三）科学性原则：公司的市值管理有其规律，应当依其规律进行科学管理， 科学研判影响公司投资价值的关键性因素，以提升上市公司质量为基础开展市值 管理工作。 （四）常态性原则：公司的市值成长是一个持续的和动态的过程，公司将及 ...

Core Viewpoint - The board of directors of Anhui Changcheng Military Industry Co., Ltd. held its seventh meeting of the fifth session, where several key resolutions were passed, including the approval of the 2025 semi-annual report and various management systems [1][2][3][4]. Group 1: Board Meeting Details - The board meeting was convened on August 25, 2025, with 8 out of 9 directors present, and was conducted in accordance with legal regulations [1]. - The meeting's resolutions included the approval of the 2025 semi-annual report, which was confirmed to be accurate and complete [2]. Group 2: Resolutions Passed - The board approved the 2025 semi-annual risk assessment report for the Weapon Equipment Group Financial Co., Ltd., with 5 votes in favor [2]. - The board also approved the Market Value Management System, the Director Departure Management System, and the Information Disclosure Postponement and Exemption Management System, each receiving unanimous support with 9 votes in favor [3][4].

Core Viewpoint - Zhejiang Biyi Electric Co., Ltd. has decided to cancel its supervisory board and amend its articles of association, which includes revising several governance systems and working rules, as well as handling business registration changes [1][2]. Group 1: Governance Structure Changes - The company will no longer have a supervisory board, with its powers transferred to the audit committee of the board of directors, and the relevant supervisory board rules will be abolished [2][3]. - Amendments to the articles of association will include the establishment of a market value management system and the authorization of the management to handle business registration changes [2][3]. Group 2: Capital Reduction and Stock Repurchase - The company has approved the repurchase and cancellation of 8,400 restricted stocks held by two employees who have left the company, resulting in a reduction of registered capital from 187,947,951 RMB to 187,939,551 RMB [2][3]. - The total number of shares will decrease by 8,400 shares due to this repurchase [2][3]. Group 3: Articles of Association Amendments - The articles of association will be revised to reflect the new governance structure, including changes to shareholder responsibilities and rights [4][5]. - Specific provisions regarding the responsibilities of shareholders and the prohibition of financial assistance for acquiring shares will be included in the revised articles [4][5].

市值管理制度 第一章 总则 第一条 为切实推动浙江比依电器股份有限公司（以下简称"公司"）提升投资价 值，增强投资者回报，规范公司市值管理工作，根据《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司监管指引第 10 号—市值管理》《上海证券交易所股票 上市规则》等法律法规、规范性文件及《公司章程》的规定，制定本制度。 第二条 本制度所称市值管理，是指公司以提高公司质量为基础，为提升公司投 资价值和股东回报能力而实施的战略管理行为。 浙江比依电器股份有限公司 第三条 公司在开展市值管理工作过程中，应当牢固树立回报股东意识，采取措 施保护投资者尤其是中小投资者利益，诚实守信、规范运作、专注主业、稳健经营， 以新质生产力的培育和运用，推动经营水平和发展质量提升，并在此基础上做好投资者 关系管理，增强信息披露质量和透明度，必要时积极采取措施提振投资者信心，推动 公司投资价值合理反映公司质量。 第四条 市值管理的基本原则： （一）合规性原则：公司应当在严格遵守相关法律法规、规范性文件和《公司章 程》等规定的前提下开展市值管理工作； （二）系统性原则：公司应当秉持系统思维、整体推进的原则，协同公司各业务 体系以 ...

Core Viewpoint - The report presents the financial performance and operational highlights of Miracll Chemical Co., Ltd. for the first half of 2025, emphasizing growth in revenue and net profit while outlining the company's strategic focus on polyurethane new materials and functional chemical products. Company Overview and Financial Indicators - Miracll Chemical Co., Ltd. is a leading manufacturer of polyurethane new materials (TPU, PUR, PUD, PBS) and functional chemical raw materials (special isocyanates, special amines) with applications across various industries including consumer electronics, automotive, and green energy [4][5]. - The company reported a slight increase in revenue of 0.02% year-on-year, totaling approximately 800.7 million yuan, while net profit attributable to shareholders rose by 25.25% to approximately 39.1 million yuan [3][4]. Business Operations - The company operates two main production bases located in Yantai, Shandong, and Hebi, Henan, focusing on the production of polyurethane new materials and functional chemical raw materials respectively [4][5]. - The TPU product line accounts for over 90% of sales, with ongoing development in other products like PUR, PUD, and PBS, which are expected to grow rapidly [4][5]. Product Characteristics and Applications - TPU is highlighted for its excellent mechanical properties, temperature resistance, and environmental durability, making it suitable for a wide range of applications from consumer electronics to automotive components [4][5]. - The company is the only publicly listed entity in China primarily focused on TPU, establishing a competitive edge through quality and innovation [4][5]. Special Isocyanates and Amines - The company specializes in producing special isocyanates such as HDI, CHDI, and PPDI, which are characterized by their superior mechanical properties and stability, suitable for high-performance applications [6][7]. - The production of special amines (PNA, PPDA, CHDA) is also emphasized, with the company holding a leading position in global production capacity for these materials [8][9]. Market Position and Competitive Advantage - The company has established a strong market presence and competitive advantage through continuous technological innovation and a focus on high-quality, differentiated products [4][5][6]. - The strategic focus on upstream supply chain integration ensures a stable supply of high-quality raw materials, enhancing the company's resilience and competitive positioning in the market [12].

Group 1 - The company held a half-year performance briefing on August 25, 2025, with key management personnel participating, including the chairman and general manager [1] - The company emphasized that market capitalization management is a key task for the year, having established a market value management system in June and approved a share buyback plan of 80 million to 100 million yuan at the end of July [1] - The company executed its first share buyback on August 14, repurchasing 3,762,300 shares for a total amount of 19,999,259 yuan (excluding transaction fees) [1] Group 2 - The company maintains a stable dividend policy, increasing the frequency and proportion of dividends to reward shareholders [1] - As of the end of June, the company has launched 199 SPD projects across 23 provinces in China and plans to develop new projects as needed [1] - The company operates 205 DTP pharmacies, with 192 directly operated and 13 franchised, and aims to significantly expand this business in the future [1] Group 3 - The acquirer plans to resolve competition issues with China National Pharmaceutical within five years through various measures such as asset restructuring [2] - The company is building a differentiated competitive system focused on "strengthening barriers, enhancing value, and exploring growth" while leveraging its state-owned enterprise background for synergy [2] - The company primarily invests in generic drug research and development, adhering to international standards, with four products approved and three in commercial production [2]